Clinical Trials Logo

Filter by:
NCT ID: NCT01118728 Terminated - Clinical trials for Ankylosing Spondylitis

Extension Study for Long Term Evaluation of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis

SUSTAIN
Start date: June 2010
Phase: Phase 2
Study type: Interventional

Primary Objective: - To assess the long term safety of Sarilumab (SAR153191/REGN88) in patients with ankylosing spondylitis (AS) Secondary Objective: - To assess the long term efficacy of Sarilumab (SAR153191/REGN88) in patients with AS

NCT ID: NCT01117818 Completed - Alzheimer's Disease Clinical Trials

Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease

Start date: September 2010
Phase: Phase 2
Study type: Interventional

This is a multiple vaccination study to find out if it is a safe treatment and what effects it has on the symptoms of early Alzheimer's disease in male and female patients aged 50 to 80 years. Approximately 40 study sites in Europe will be involved. Patients will be randomized to receive either AFFITOPE AD02 or placebo. Each patient's participation will last 1 year.

NCT ID: NCT01117350 Completed - Clinical trials for Diabetes Mellitus, Type 2

Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure

EAGLE
Start date: July 2010
Phase: Phase 4
Study type: Interventional

Primary objective: To demonstrate the superiority of insulin glargine over liraglutide in terms of percentage of patients reaching a Glycosylated Haemoglobin (HbA1c) < 7% at the end of the comparative period (24 weeks) in Type 2 diabetic patients failing lifestyle management and oral agents Secondary objectives of the comparative period (24 weeks): >To assess the effect of insulin glargine in comparison with liraglutide on: - HbA1c level - Percentage of patients whose HbA1c has decreased but remains >= 7% at the end of the comparative period - Percentage of patients whose HbA1c has increased at the end of the comparative period - Fasting Plasma Glucose (FPG) - 7-point Plasma Glucose (PG) profiles - Hypoglycemia occurrence - Body weight - Adverse events Objectives of the extension period (24 weeks): >To assess the effect of insulin glargine in patients not adequately controlled with liraglutide on: - HbA1c level - FPG - 7-point PG profiles - Hypoglycemia occurrence - Body weight - Adverse events

NCT ID: NCT01117012 Completed - Cystic Fibrosis Clinical Trials

Rollover Study of VX-770 in Cystic Fibrosis Subjects

Start date: July 2010
Phase: Phase 3
Study type: Interventional

The primary objective of the study was to evaluate the safety of long-term VX-770 treatment in participants with cystic fibrosis (CF). The secondary objective of the study was to evaluate the efficacy of long-term VX-770 treatment in subjects with CF.

NCT ID: NCT01112865 Completed - Clinical trials for Growth Hormone Deficiency

Cross Over Convenience And Preference Study Of New Mark VII Compared To Genotropin Pen In Pediatric And Adult Subjects

CHOOSE
Start date: August 2010
Phase: Phase 3
Study type: Interventional

Convenience and preference for the new Mark VII pen compared to the current Genotropin pen will be assessed using a questionaire. it is expected that the new pen will be preferred or at least no different to the current pen.

NCT ID: NCT01112579 Completed - Heart Failure Clinical Trials

Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Heart Failure

DEFEAT-HF
Start date: April 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the feasibility of spinal cord stimulation (SCS) as a chronic therapy for systolic heart failure.

NCT ID: NCT01112033 Completed - Clinical trials for Hepatitis C, Chronic

Biliverdin Reductase A in Chronic Hepatitis C Virus Infection

Start date: June 2010
Phase: N/A
Study type: Observational

In this project, the investigators aim to study the role of biliverdin reductase A (BLVRA) in HCV infected patients prior and during/after standard antiviral therapy in association with viral clearance, disease progression and treatment response and in comparison with healthy subjects.

NCT ID: NCT01110967 Completed - Clinical trials for Degenerative Disc Disease, Lumbar

Satellite™ PEEK Nucleus Replacement Retrospective Analysis

Start date: April 2010
Phase: N/A
Study type: Observational

The Satellite™ Retrospective Analysis is an international, retrospective, multi-center, non-interventional post-marketing study designed to document and analyze existing data with the device in a "real-world" setting. The purpose of this study is to evaluate number of adverse device effects (ADEs), serious adverse device effects (SADEs) and serious adverse event (SAEs) and early clinical effectiveness for the Satellite™ Nucleus Replacement in a standard clinical practice. Data collection will include information on health related quality of life (QoL), physical functioning and adverse event after nucleus replacement surgery. Radiographic measures will also be assessed to evaluate changes in disc height at the operated level and changes in segmental range of motion. All patients who were implanted with a Satellite™ Nucleus Replacement Prosthesis in the participating sites are eligible for participation in the Satellite ™ Retrospective Analysis.

NCT ID: NCT01110408 Terminated - Clinical trials for Complicated Urinary Tract Infections or Pyelonephritis

A Safety and Tolerability Study of Doripenem Compared With Cefepime in Children Hospitalized With Complicated Urinary Tract Infections

Start date: December 2010
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of doripenem compared to cefepime in children hospitalized with complicated urinary tract infections.

NCT ID: NCT01107886 Completed - Clinical trials for Type 2 Diabetes Mellitus

Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications

SAVOR- TIMI 53
Start date: May 2010
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether saxagliptin can reduce the risk of cardiovascular events when used alone or added to other diabetes medications